Cargando…
Atezolizumab Induces Necroptosis and Contributes to Hepatotoxicity of Human Hepatocytes
Atezolizumab is an immune checkpoint inhibitor (ICI) targeting PD-L1 for treatment of solid malignancies. Immune checkpoints control the immune tolerance, and the adverse events such as hepatotoxicity induced by ICIs are often considered as an immune-related adverse event (irAE). However, PD-L1 is a...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380327/ https://www.ncbi.nlm.nih.gov/pubmed/37511454 http://dx.doi.org/10.3390/ijms241411694 |